Divis Laboratories

The filing further said that the financials of the company won't be impacted and the penalty will be paid within the prescribed timeline

The PCR (Put Call Ratio) of these 3 stocks is above 1, implying presence of higher open positions in Puts as against Calls, shows the NSE options data.

Among existing gainers, Divi's Lab and Shriram Finance seem poised for further gains, whereas losers IndusInd Bank and Nestle too look promising on technical charts; check key levels.

Shares of Divi's Laboratories surged up to 5 per cent at Rs 4960 per share on the BSE in Wednesday's intraday deals

Solara Active Pharma Sciences, Indoco Remedies, Dishman Carbogen Amcis, Krishna Institute of Medical Sciences, Divi's Lab, Strides Pharma, Narayana Hrudayalaya and Vijaya Diagnostic were up 5 per cent

Stock Market Live updates on August 5: Indian bourses are staring at a bear attack on Monday after heavy sell-off in global peers. The GIFT Nifty futures also indicated a gap-down start,

Analysts say pharmaceutical company's stock fully priced in

At 11:49 am; Nestle India (Rs 2,385.45), Pidilite Industries (Rs 2,988.45) and Divi's Labs (Rs 4,343.80) were trading higher by up to 1% higher, as compared to a near 5% decline in the BSE Sensex.

Since April 2024, Metro Brands has been trading within a consolidation range of approximately Rs 1,020 to Rs 1,120

Divi's Labs net profits rose by 67 per cent to Rs 538 crore in the January-March quarter of FY24 compared to Rs 321 crore in the corresponding period last year

Divi's Labs Q2 result: The revenue from operations, however, rose 3 per cent to Rs 1,909 crore in the period from Rs 1,855 crore last year

Pharm index has broken out on upside, with the positive rally anticipated to hit 14,450

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation reveals a "Descending Triangle" violation

Technically, the Nifty Pharma index needs to immediate hurdle at 13,500, for further upside to 14,250.

Divi's Laboratories on Monday said its consolidated net profit declined by 18 per cent to Rs 494 crore in the second quarter of the current financial year. The drug firm had reported a net profit of Rs 606 crore in the July-September period of last fiscal. Revenue from operations declined to Rs 1,854 crore in the September quarter as against Rs 1,987 crore in the year-ago period. Shares of the company on Monday ended 8.63 per cent at Rs 3,422 apiece on the BSE.

The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity of APIs going off-patent over FY23-25.

Ebitda margin contracted by 180 basis points year-on-year to 41.5 per cent in Q2FY22 due to higher other expenses/employee costs.

Merck & Co's Covid-19 antiviral pill, Molnupiravir, reduced the risk of hospitalisation or death by 50 per cent

The board has recommended a dividend of Rs 20 (i.e. 1,000 per cent) per equity share of face value Rs 2 each for the financial year 2020-21

Currently, Divis Labs stands at the 30th position among companies having market-cap of over Rs 1 trillion.